Federal prosecutors allege that approximately $174 million of roughly $268 million paid on disputed skin-substitute claims ultimately reached Michael McMillan and his Protectus companies through reimbursement-linked invoices, while participating medical providers allegedly retained approximately $94 million as disguised kickbacks.
WASHINGTON, DC, August 23, 2026 — Federal prosecutors say Las Vegas businessman Michael McMillan and a group of companies operating under the Protectus name received approximately $174 million through an alleged wound-care reimbursement system funded by Medicare, TRICARE, and CHAMPVA payments.
The money did not necessarily travel directly from federal program accounts into Protectus accounts, because the indictment describes providers receiving reimbursement first and then paying Protectus invoices calculated as approximately 60% to 70% of each successful claim.
Participating physicians, podiatrists, nurse practitioners, and other providers allegedly kept the remaining 30% to 40%, producing about $94 million in retained payments that prosecutors characterize as illegal kickbacks disguised as commercial rebates or discounts.
That distinction best explains the prosecution’s $174 million figure, which represents the portion allegedly collected by McMillan’s entities after successful government reimbursement rather than a separate amount added above the approximately $268 million paid on disputed claims.
McMillan has not been convicted, every accusation remains unproven, and prosecutors must establish the charged conspiracies and transaction offenses beyond a reasonable doubt before any jury may treat the government’s description of Protectus revenue as established criminal proceeds.
What the $174 Million Figure Actually Measures
The Northern District of Texas announcement describing the McMillan indictment says Protectus received approximately $174 million after allegedly offering skin-substitute products through arrangements that guaranteed participating medical providers substantial profits whenever government healthcare programs paid their claims.
The charging document identifies approximately $268 million as the amount government programs allegedly paid for relevant skin-substitute claims, meaning the claimed Protectus receipts represented nearly two-thirds of the total reimbursement flowing through the challenged commercial structure.
Simple arithmetic places the alleged Protectus share at approximately 64.9% of the government payments, while the approximately $94 million retained by providers represents approximately 35.1%, percentages closely matching the 60-to-70 and 30-to-40 allocation ranges described throughout the indictment.
Those percentages help prosecutors present a coherent economic theory, but they do not independently prove that every invoice followed an identical formula, every payment was unlawful, every provider understood the same arrangement, or every dollar remained traceable to a false claim.
The government will still need transaction-level evidence showing how particular reimbursements produced corresponding invoices, when providers transferred funds, which Protectus entity received each payment, and what McMillan allegedly understood about the arrangement’s purpose and legal consequences.
Federal Programs Allegedly Supplied the Reimbursement Stream
Medicare occupies the most detailed position within the indictment, although prosecutors also identify TRICARE and the Civilian Health and Medical Program of the Department of Veterans Affairs, commonly known as CHAMPVA, as government programs allegedly affected by the arrangement.
These programs serve different populations, including older Americans, eligible people with disabilities, military members, retirees, veterans’ family members, survivors, and other qualifying beneficiaries whose medical care depends upon accurately administered and financially sustainable public benefits.
Prosecutors allege that providers submitted skin-substitute claims to those programs, received reimbursement when claims succeeded, and then used portions of the resulting payments to satisfy Protectus invoices whose amounts depended upon the reimbursement actually collected.
The indictment therefore portrays federal healthcare payments as the economic source of the approximately $174 million even though providers allegedly acted as intermediaries between government payers and the Protectus companies during the collection process described by investigators.
Defense counsel may emphasize that indirect economic origin does not automatically establish criminal derivation, particularly when products were delivered, wound treatment occurred, providers-controlled claims, and corporate accounts could contain revenue from lawful as well as disputed business activity.
Protectus Allegedly Connected Products, Claims, and Collections
The indictment groups Protectus LLC, Protectus Technologies LLC, Protectus Consulting LLC, Prestige Medical Consultants LLC, Velare Wound Care LLC, and Amnio ReGen Solutions LLC under the collective Protectus label, alleging that McMillan owned and controlled all six Nevada companies.
Prosecutors say those entities supplied skin substitutes, recruited medical practices, assisted billing activity, monitored reimbursement, generated invoices after payment, collected provider transfers, calculated representative commissions, and maintained records spanning the alleged nationwide operation.
That combination allegedly gave Protectus visibility across the full commercial cycle, from product placement and provider recruitment through claim submission, payment confirmation, invoice calculation, collection, accounting, compensation, and later use of corporate receipts.
For prosecutors, centralized visibility may support arguments concerning knowledge and intent, while defense lawyers can contend that distributors commonly coordinate inventory, customer credit, billing support, collections, and representative compensation without transforming legitimate commercial services into healthcare fraud.
Corporate form will also matter because the government must connect McMillan personally with relevant decisions and records, rather than assuming that ownership alone proves he knew every communication, invoice, coding entry, provider representation, or employee action across related businesses.
No Upfront Payment Allegedly Removed Ordinary Provider Risk
Participating practices allegedly obtained skin-substitute products without paying Protectus before treatment, allowing providers to apply materials and seek government reimbursement before any corresponding product invoice became due through the challenged arrangement described by prosecutors.
When a claim was denied, Protectus allegedly charged the provider nothing, insulating the practice from product expense and making successful federal reimbursement the trigger for a financial obligation to the companies controlled by McMillan.
When payment arrived, however, Protectus allegedly invoiced approximately 60% to 70% of the collected reimbursement, leaving providers with a predetermined share that could equal thousands of dollars for each approved skin-substitute application billed to public programs.
Prosecutors characterize this structure as more than generous trade credit because the provider’s final cost allegedly depended upon government payment, while denied claims eliminated liability and successful claims guaranteed the medical practice a substantial financial margin.
The defense may argue that deferred invoices, risk-sharing, rebates, discounts, and customer financing can serve legitimate commercial purposes, requiring prosecutors to prove unlawful inducement and intentional deception rather than relying merely upon an unconventional or profitable business model.
Provider Retention Allegedly Reached $94 Million
The approximately $94 million allegedly retained by providers represents the other major component of the government’s money-flow calculation, broadly reconciling with the $174 million attributed to Protectus when both figures are compared against approximately $268 million in total payments.
Prosecutors call the provider share illegal remuneration because practices allegedly received guaranteed profits tied directly to claims for Protectus products, creating financial incentives to select, apply, and bill those products for beneficiaries covered by federal programs.
Commercial discounts are not inherently criminal, and federal law recognizes carefully defined protections for some arrangements, but the indictment alleges that these payments were concealed, reimbursement-dependent, and intended to generate federally funded orders rather than reflect ordinary product pricing.
Each participating provider may nevertheless occupy a different factual position concerning contract terms, clinical independence, billing control, knowledge, disclosure, reliance, product use, and retained funds, making broad public assumptions about unnamed practitioners especially unreliable before evidence is tested.
Percentage-Based Invoices Allegedly Preserved the Split
One accounting example described in the indictment concerns approximately $53,625.60 collected by a provider, approximately $16,087.68 retained by that practice, and a Protectus Technologies invoice for approximately $37,537.92, reflecting an exact 30-to-70 allocation.
Another episode allegedly involved a Texas practice disputing an invoice exceeding $82,000 because the calculation left a 35% provider share even though a newer agreement reportedly promised the practice 40% of successful reimbursement.
McMillan allegedly directed an employee to correct that disputed invoice, an interaction prosecutors may present as evidence of personal control over the reimbursement formula, while defense counsel may dispute its context, meaning, accuracy, or legal significance.
Individual examples can make the alleged arrangement understandable for jurors, but prosecutors must still show that representative documents reflect a broader system and cannot convert every company receipt into criminal proceeds through isolated accounting entries alone.
Invoices, reimbursement notices, bank statements, internal messages, commission reports, contracts, claim records, and accounting ledgers may therefore become decisive evidence concerning whether the approximately $174 million resulted from consistent percentage splits or varied commercial relationships.
Acquisition-Price Disclosures Support the Fraud Theory
The indictment alleges that Medicare claims required providers to disclose their actual acquisition price, including applicable discounts, rebates, refunds, and other adjustments, through information entered within Box 19 of the professional claim form used for reimbursement.
Prosecutors contend that McMillan or Protectus personnel submitted claims, assisted practices, or advised providers to report amounts exceeding the prices they effectively paid after reimbursement-linked reductions, thereby concealing the economic reality of the alleged provider profit.
Under that theory, Protectus could collect approximately $174 million only because government programs paid claims using inaccurate information about product cost, while providers allegedly preserved approximately $94 million through undisclosed adjustments presented as lawful rebates or discounts.
The defense can challenge whether reporting rules were sufficiently clear, whether the described adjustments changed acquisition cost, whether providers controlled final submissions, whether particular statements were material, and whether McMillan knowingly caused any inaccurate representation.
This pricing issue may bridge a profitable distribution model and the charged healthcare fraud conspiracy, because large receipts are not illegal without proof that deception or prohibited remuneration caused government programs to release the underlying money.
Billing Assistance Allegedly Helped Convert Claims into Revenue
Protectus employees allegedly assisted providers with missing information, reimbursement questions, claim corrections, payment monitoring, and resubmissions, activities that prosecutors may use to show the companies were operational participants rather than passive product sellers awaiting ordinary customer payments.
During one episode described by prosecutors, a practice reported one Medicare payment and one denial, after which a Protectus employee allegedly identified missing Box 19 information, recommended resubmission, and generated a percentage-based invoice for the successful claim.
Prosecutors may argue that such sequences connected billing assistance directly with Protectus collections, because resolving claim problems increased reimbursed amounts from which the company’s calculated invoices and sales representatives potentially received commissions under their compensation arrangements.
Defense attorneys can respond that vendors routinely support customers with coding, documentation, coverage, and administrative questions, making the content, accuracy, intent, and certification responsibility surrounding each communication more important than the mere existence of assistance.
The approximately $174 million figure will therefore require more than aggregate bank totals, because the government must persuade jurors that company involvement knowingly advanced false or kickback-tainted claims rather than legitimate reimbursement for medically appropriate products delivered to patients.
Sales Representatives Allegedly Received $27 Million
Sales representatives allegedly recruited physicians, podiatrists, nurse practitioners, and other providers by explaining the Protectus arrangement, including the percentage of successful government reimbursement that a participating practice could expect to retain after paying its invoice.
The indictment estimates that Protectus paid approximately $27 million to representatives, with commission reports and communications allegedly linking compensation to insurer payments generated by the medical practices each representative recruited into the network.
That $27 million should not be added to the approximately $268 million reimbursement total, because prosecutors describe representative commissions as downstream expenditures from money already received by Protectus rather than a fourth independent share of federal payments.
Likewise, the $27 million should not automatically be treated as additional revenue above the approximately $174 million, because it allegedly came from corporate collections and reduced the amount remaining after Protectus compensated its sales network.
Percentage-based commissions are common throughout lawful commerce, so prosecutors must connect representative compensation with the alleged kickback and fraud objectives, while defense counsel may separate ordinary sales incentives from any provider’s independent clinical or billing decisions.
The $174 Million Became the Alleged Corporate Revenue Center
The reimbursement chain described by prosecutors begins with a skin-substitute application, proceeds through a claim submitted to Medicare, TRICARE, or CHAMPVA, and continues when government payment reaches a participating provider’s account after administrative approval.
Protectus then allegedly calculated an invoice from the exact reimbursement, collected about 60% to 70%, paid commissions tied to the provider relationship, and retained the remaining corporate proceeds for operations, distributions, investments, transfers, or asset acquisitions.
This sequence explains why the approximately $174 million matters more than a conventional gross-sales figure, because prosecutors contend the money embodied a recurring relationship between federal reimbursement, provider profit, company collection, and sales compensation.
The NBC 5 Dallas-Fort Worth report on the newly unsealed healthcare cases described allegations that providers kept 30% to 40%, representatives received approximately $27 million, and McMillan later used proceeds for homes, vehicles, and a private aircraft.
Public attention may focus on the dramatic totals and luxury assets, but a federal trial would require admissible evidence linking those visible outcomes to specific allegedly unlawful claims, transfers, decisions, and states of mind.
Tracing the Receipts Could Define the Case
Financial investigators can compare government reimbursement records with provider deposits, Protectus invoices, incoming corporate transfers, representative commissions, tax filings, accounting entries, intercompany movements, asset purchases, and communications explaining the purpose of particular payments.
If reimbursement and invoice amounts repeatedly preserve the alleged percentage formula, prosecutors may argue that the pattern corroborates a coordinated system, while defense experts may identify exceptions, lawful revenue, accounting errors, contractual differences, or legitimate adjustments.
Commingled accounts could create significant disputes because lawful and allegedly unlawful receipts may have entered the same balances, requiring accepted tracing methods to determine whether later payments involved criminally derived property and in what amount.
The defense may also argue that products physically delivered to providers retained legitimate economic value, complicating any assertion that every dollar Protectus collected represented pure fraud proceeds rather than revenue containing recoverable product and service components.
Prosecutors may answer that claims generated through prohibited remuneration or material price misrepresentations were ineligible for payment, making resulting collections criminal proceeds even when products were applied, and some patients obtained clinical benefit.
McMillan’s Alleged Control Remains Essential
The government identifies McMillan as owner and controller of the six Protectus companies, but criminal liability still requires evidence that he knowingly joined the charged agreements and understood the allegedly unlawful purposes behind relevant payments and representations.
Prosecutors may rely upon meetings, invoice instructions, pricing statements, communications, account authority, corporate records, compensation decisions, and asset transactions to argue that McMillan directed central features rather than remaining distant from daily operations.
The indictment describes a March 2024 meeting during which McMillan allegedly discussed average provider rebates, illustrated potential monthly profit, and addressed claim pricing, statements that could become important if witnesses and records authenticate their wording and context.
Defense lawyers can challenge witness memory, interpretation, attribution, incomplete recordings, ambiguous language, commercial explanations, employee independence, and the possibility that particular practices departed from McMillan’s instructions or written company policies during nationwide expansion.
Ownership, wealth, and managerial status cannot replace proof of knowledge, meaning jurors must evaluate what McMillan actually authorized, learned, intended, and understood while the approximately $174 million allegedly accumulated across several entities and years.
Luxury Assets Allegedly Followed Protectus Collections
Counts Three through Nine identify seven transactions totaling approximately $6.28 million involving four real-estate interests, a Lamborghini Urus, a Cadillac Escalade, and a Cessna Citation VII aircraft allegedly purchased with criminally derived property.
The charged sequence begins with a Dallas condominium payment in December 2021 and concludes with a September 2025 aircraft transaction linked to an account controlled by Elite Elevated Enterprises LLC, according to the government’s transaction allegations.
Those counts focus on monetary dealings exceeding $10,000 in allegedly criminally derived property, meaning prosecutors need not prove that every acquisition was structured to conceal ownership, though they must establish statutory knowledge and a criminal source.
Defense counsel can challenge funding history, account ownership, lawful receipts, loans, savings, investments, tracing methods, transaction purpose, and McMillan’s knowledge separately for every charged purchase rather than treating the assets as one undifferentiated lifestyle narrative.
Expensive property may make the approximately $174 million allegation visually compelling, yet prestige and consumption do not prove healthcare fraud, because lawful business income can finance luxury purchases and jurors must apply statutory elements without moralizing wealth.
Seizure Does Not Equal Final Forfeiture
Federal authorities reported seizing assets valued at approximately $35 million during the investigation, a substantial figure that illustrates the scope of government restraint while remaining distinct from the approximately $174 million allegedly received by Protectus.
Seizure places property under governmental control during proceedings but does not establish guilt, permanent forfeiture, precise loss, or ultimate ownership, leaving tracing, valuation, liens, proportionality, and third-party claims open to further litigation before final judgment.
The indictment seeks forfeiture tied to alleged conspiracy proceeds and the seven monetary transactions, while federal law may permit substitute-property proceedings if directly traceable assets become unavailable, diminished, transferred, or inseparably commingled under applicable standards.
An eventual forfeiture result could therefore differ substantially from the amount seized, the value charged through particular transactions, the alleged $174 million in corporate receipts, or the approximately $268 million paid by federal programs.
False Claims Do Not Necessarily Mean No Treatment Occurred
The phrase false claims can describe nonexistent treatment, medically unnecessary services, inaccurate pricing, hidden kickbacks, improper quantities, ineligible providers, falsified diagnoses, or other representations that could affect whether a healthcare program should release payment.
The McMillan indictment emphasizes alleged remuneration and acquisition-price disclosures, so responsible reporting should not assume that every skin substitute went unused, every application lacked clinical value, or every associated healthcare professional knowingly participated in wrongdoing.
Prosecutors can nevertheless contend that claims become ineligible when prohibited financial inducements corrupt purchasing decisions or material pricing information is concealed, even when a product was physically delivered and applied to a patient’s wound.
Defense attorneys may separate medical value from payment compliance, challenging whether remuneration was unlawful, whether price information was inaccurate, whether any misstatement was material, and whether the government can prove intent for specific claims within aggregate totals.
This distinction matters for patients because skin substitutes can support healing in properly selected chronic wounds, while indiscriminate suspicion could discourage appropriate treatment or stigmatize beneficiaries whose medical histories are unrelated to any provider’s financial arrangements.
The Defense Can Challenge Every Link in the Flow
McMillan’s defense can contest whether any provider agreement violated federal kickback restrictions, whether commercial terms received available protection, whether claims contained material falsehoods, and whether McMillan knowingly joined either charged conspiracy during the relevant period.
Counsel can also challenge the government’s aggregation of company receipts, arguing that varied products, providers, contracts, programs, invoices, dates, and account movements require individualized analysis rather than one assumption applied across approximately $174 million.
Provider independence may become especially important if clinicians selected medically necessary products, controlled final billing, understood discounts differently, or submitted information without direction from McMillan or personnel authorized to speak for Protectus during the claims process.
Financial experts could dispute tracing, allocation, legitimate value, commingling, invoice interpretation, representative compensation, and whether corporate transfers represented ordinary expenses, intercompany services, loans, distributions, reimbursements, or proceeds from criminal activity during the relevant years.
The government carries the burden throughout, and a large dollar figure cannot cure evidentiary gaps concerning agreement, falsity, materiality, causation, remuneration, intent, attribution, knowledge, transaction source, or any other required element under federal criminal law.
Compliance Lessons Reach Beyond Protectus
Wound-care manufacturers, distributors, medical practices, billing companies, and marketing organizations should examine arrangements where product obligations disappear after denials, invoice amounts depend upon reimbursement, and providers retain guaranteed percentages of successful government payments.
Compliance teams should compare reported acquisition prices with final economic cost, review discount and rebate disclosures, test representative compensation, preserve clinical independence, and ensure vendors do not control material claim information submitted under provider credentials.
Organizations should preserve contracts, emails, text messages, claim forms, reimbursement notices, invoices, commission reports, bank statements, tax records, and ownership documents because ordinary business materials can later establish intent, control, consistency, or contradictory explanations.
Independent sampling can identify whether percentage formulas recur across providers, whether denied claims erase product obligations, whether unusual profits cluster around specific representatives, and whether corrective action becomes necessary before questionable practices spread nationally.
Reputation Moves Faster Than Federal Litigation
An indictment linking approximately $174 million in healthcare receipts with alleged kickbacks and luxury assets can dominate search results immediately, unsettling employees, providers, patients, commercial partners, and financial institutions years before litigation reaches a final outcome.
Organizations facing that imbalance may need disciplined crisis public-relations management that separates accusations from adjudicated facts, protects confidential information, coordinates authorized statements, corrects verifiable errors, and avoids commentary that could undermine legal strategy.
Longer-term reputation-rebuilding strategies can document procedural developments, explain independently verified reforms, answer stakeholder concerns, and preserve accurate searchable context without concealing material facts or presenting unresolved allegations as exoneration through responsible public communication.
McMillan, individual Protectus entities, medical providers, employees, representatives, patients, and third parties may occupy sharply different legal positions, making tailored communication essential whenever a collective response could imply guilt, expose protected information, or contradict court filings.
The National Takedown Magnified the Case
The McMillan prosecution emerged during the 2026 National Health Care Fraud Takedown, which federal officials said produced charges against 455 defendants concerning more than $6.5 billion in alleged false claims across numerous districts and healthcare sectors.
Within the Northern District of Texas, thirteen defendants faced seven cases involving more than $365 million in alleged fraudulent billing, making the Protectus matter the district’s largest announced prosecution by claimed reimbursement value during that coordinated action.
That national setting explains the extraordinary visibility around the $174 million allegation, but accusations against unrelated defendants cannot establish McMillan’s guilt and should not influence jurors evaluating evidence tied only to his nine charged counts.
What Happens Next in Federal Court
Pretrial proceedings may examine search procedures, electronic evidence, provider agreements, Box 19 requirements, claim data, corporate accounting, bank records, representative commissions, witness credibility, expert methods, and statements attributed to McMillan or Protectus employees.
Prosecutors must connect the approximately $174 million with allegedly false or kickback-tainted reimbursements while proving McMillan’s knowing participation, whereas defense counsel can attack the legal characterization and factual reliability of each link within that chain.
If convictions eventually occur, restitution, forfeiture, and sentencing would require individualized findings concerning sustained counts, proven loss, legitimate value, traced proceeds, recovered assets, criminal history, role assessments, obstruction questions, and other statutory considerations.
No responsible prediction can be made from the indictment alone because discovery, motion rulings, witness cooperation, expert analysis, factual stipulations, plea discussions, trial evidence, jury findings, and judicial discretion may substantially reshape the prosecution.
Until a jury returns verdicts or another lawful resolution ends the case, Michael McMillan remains presumed innocent, the approximately $174 million remains an allegation, and every disputed claim, invoice, rebate, commission, transfer, and asset remains subject to adversarial testing.
